One-A-Day Tablet Treats Common Infection for Neck Cancer Patients Undergoing Radiation Therapy
Dr. Rene-Jean Bensadoun from Centre Antoine Lacassagne in Nice, and international colleagues, studied patients in 36 centers who had completed radiotherapy for head and neck cancer and had oropharyngeal candidiasis confirmed by examination or fungal culture.
One group of 141 patients were given daily a bioadhesive tablet containing 50mg of miconazole, developed by BioAlliance Pharma, a French biopharmaceutical company, the other 141 patients received a mouth gel (MBG) containing 125mg of miconazole four times daily for 14 days.
"We found that the daily bioadhesive buccal tablet achieved the same efficacy as the gel, but required one-tenth as much miconazole, and could be given on a much more convenient schedule," Dr. Bensadoun said.
"Patients currently need to apply the gel four times a day, which is disruptive to their day and increases the risk that they will miss treatments and suffer the discomfort of candidiasis for a longer period of time."
"While oropharyngeal candidiasis is perhaps not a dangerous infection, it is unpleasant, and anything we can do as oncologists to improve the quality of life of cancer patients is a positive thing."
"Head and neck cancer patients suffer not only from their disease, but experience many acute and chronic side-effects due to treatment", comments Dr. Dirk Schrijvers from the Department of Medical Oncology of the ZNA Middelheim, Antwerp, Belgium. Everything that can improve the quality of life of these patients during and after treatment will have an impact on treatment compliance and disease outcome. By providing a simpler way of controlling oral candidiasis, patient compliance may increase.
About the European Society for Medical Oncology (ESMO)
ESMO is Europe's leading professional society providing education and clinical guidelines for medical oncologists and other healthcare professionals, working to ensure optimal care for cancer patients. Currently, with 4,500 members, ESMO is represented in every European country and the six major geographical areas of the world. Since its inception in 1975, ESMO has consistently promoted its belief that every cancer patient is entitled to the best possible treatment available. The use of medicine is now a fundamental aspect of cancer therapy and, consequently, cancer patients need to be treated by qualified medical oncologists. Through its flagship scientific journal, Annals of Oncology, ESMO publishes research results on all aspects of clinical oncology. Donations to the ESMO Foundation support ESMO activities as well as cancer research. More information about the Society is available at http://www.esmo.org
About the 2nd ESEC Conference
This unique educational conference is designed to offer updates on state-of-the-art oncology for the major tumor types as well as special interactive sessions for young medical oncologists. Highlighting the conference are new developments in treatment, advances in basic science and health services, as well as methods of providing supportive care to cancer patients. Special sessions focus on new ESMO Minimum Clinical Recommendations, how to handle medical oncology emergencies, and cancer in Central and Eastern Europe.
Reference URL
http://www.esmo.org/PressRoom
SOURCE: http://www.alphagalileo.org
One-A-Ziua Tablet trateazã comunã de infectare pentru gâtului Rac pacienþilor supuºi radioterapia - One-A-Day Tablet Treats Common Infection for Neck Cancer Patients Undergoing Radiation Therapy - articole medicale engleza - startsanatate